We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+39.96%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$1.48B
AUM Growth
+$386M
Cap. Flow
+$89.6M
Cap. Flow %
6.06%
Top 10 Hldgs %
43.47%
Holding
92
New
20
Increased
28
Reduced
19
Closed
16

Top Buys

Rank Stock Value
1
ALHC icon
Alignment Healthcare
ALHC
+$17.8M
2
CYTK icon
Cytokinetics
CYTK
+$16.5M
3
VERA icon
Vera Therapeutics
VERA
+$12.7M
4
CNC icon
Centene
CNC
+$12.1M
5
ISRG icon
Intuitive Surgical
ISRG
+$12M

Top Sells

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$26M
2
BSX icon
Boston Scientific
BSX
+$25.9M
3
DXCM icon
DexCom
DXCM
+$17.5M
4
GEHC icon
GE HealthCare
GEHC
+$14.8M
5
EHC icon
Encompass Health
EHC
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 92.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$21.6B
$230M 15.59%
1,600,000
– –
CYTK icon
2
Cytokinetics
CYTK
$10.7B
$76.9M 5.21%
1,400,000
+400,000
+40% +$16.5M
THC icon
3
Tenet Healthcare
THC
$20.2B
$60.9M 4.12%
300,000
+25,000
+9% +$4.44M
MLYS icon
4
Mineralys Therapeutics
MLYS
$2.37B
$56.9M 3.85%
1,500,000
-1,200,000
-44% -$26M
VERA icon
5
Vera Therapeutics
VERA
$2.19B
$49.4M 3.34%
1,700,000
+550,000
+48% +$12.7M
CYTK icon
6
CALL
Cytokinetics
CYTK
$10.7B
$41.2M 2.79%
750,000
+250,000
+50% +$10.3M
QURE icon
7
uniQure
QURE
$3.03B
$35M 2.37%
600,000
-750,000
-56% -$13.6M
BTSG icon
8
BrightSpring Health Services
BTSG
$12.5B
$34M 2.3%
1,150,000
-100,000
-8% -$2.32M
BSX icon
9
Boston Scientific
BSX
$69.4B
$29.3M 1.98%
300,000
-250,000
-45% -$25.9M
NAMS icon
10
PUT
NewAmsterdam Pharma
NAMS
$3.14B
$28.4M 1.92%
+1,000,000
New +$24M
REGN icon
11
Regeneron Pharmaceuticals
REGN
$79.4B
$28.1M 1.9%
50,000
– –
ALHC icon
12
Alignment Healthcare
ALHC
$2.76B
$27.9M 1.89%
1,600,000
+1,200,000
+300% +$17.8M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$30B
$27.4M 1.85%
60,000
+5,000
+9% +$2.04M
NVS icon
14
Novartis
NVS
$293B
$25.6M 1.74%
200,000
– –
EHC icon
15
Encompass Health
EHC
$10.9B
$25.4M 1.72%
200,000
-120,000
-38% -$14.3M
EWTX icon
16
Edgewise Therapeutics
EWTX
$4.79B
$24.3M 1.65%
1,500,000
+500,000
+50% +$7.09M
AZN icon
17
AstraZeneca
AZN
$250B
$23M 1.56%
150,000
+50,000
+50% +$7.57M
RDNT icon
18
RadNet
RDNT
$5.4B
$22.9M 1.55%
300,000
-100,000
-25% -$6.49M
RYTM icon
19
Rhythm Pharmaceuticals
RYTM
$7.45B
$22.2M 1.5%
220,000
+100,000
+83% +$9.28M
NVO
20
PUT
Novo Nordisk
NVO
$199B
$22.2M 1.5%
+400,000
New +$23.4M
NBIX icon
21
Neurocrine Biosciences
NBIX
$16.8B
$21.1M 1.42%
150,000
– –
CAH icon
22
Cardinal Health
CAH
$55.6B
$20.4M 1.38%
130,000
-10,000
-7% -$1.54M
RZLT icon
23
Rezolute
RZLT
$474M
$18.8M 1.27%
2,000,000
+200,000
+11% +$1.33M
RVMD icon
24
Revolution Medicines
RVMD
$41.9B
$18.7M 1.26%
400,000
+75,000
+23% +$2.94M
DGX icon
25
Quest Diagnostics
DGX
$25.9B
$16.2M 1.1%
85,000
-65,000
-43% -$11.5M
1
2 3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
NSCM
New South Capital Management Memphis, Tennessee $2.09B AUM 33.67% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return

Integral Health Asset Management's Q3 2025 Portfolio in Review

As of Q3 2025, Integral Health Asset Management held 92 positions worth $1.48B, up 35% from $1.09B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Integral Health Asset Management deployed $89.6M of net new capital in Q3 2025, opening 20 new positions and adding to 28 existing holdings. Its largest new stake was Centene: 400,000 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Mineralys Therapeutics, an estimated $26M trimmed.

  • Integral Health Asset Management's largest Q3 2025 buy was Centene: 400,000 shares worth $14.3M.
  • Integral Health Asset Management added most to Alignment Healthcare in Q3 2025, an estimated $17.8M increase.
  • Integral Health Asset Management's biggest Q3 2025 reduction was Mineralys Therapeutics, cutting an estimated $26M.
  • Integral Health Asset Management fully exited DexCom in Q3 2025, selling an estimated $17.5M.
  • Integral Health Asset Management's ten largest holdings make up 43% of its $1.48B portfolio in Q3 2025.
  • Integral Health Asset Management opened 20 new positions and closed 16 in Q3 2025.
  • Integral Health Asset Management's portfolio value rose 35% quarter-over-quarter to $1.48B.

Based on Integral Health Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.